Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 3/20 | 0.59 |
| ▸ | JAK3 | P52333 | 4/20 | 0.55 |
| ▸ | JAK1 | P23458 | 4/20 | 0.55 |
| ▸ | JAK2 | O60674 | 3/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 4/20 | 0.55 |
| ▸ | BTK | Q06187 | 2/20 | 0.55 |
| ▸ | AKT2 | P31751 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | PRKACG | P22612 | 1/20 | 0.51 |
| ▸ | PRKACB | P22694 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515055 | 0.89 | PAK1 (0.74) | PAK1JAK3JAK1JAK2TYK2 | |
| SCHEMBL9967045 | 0.85 | KIT (0.65) | PAK1JAK3JAK2KITBTK | |
| SCHEMBL9967264 | 0.85 | JAK3 (0.56) | PAK1JAK3JAK1JAK2KIT | |
| SCHEMBL9966948 | 0.85 | JAK2 (0.59) | PAK1JAK3JAK1JAK2KIT | |
| SCHEMBL9967215 | 0.84 | RPS6KB1 (0.58) | PAK1JAK3JAK2KITBTK | |
| SCHEMBL9967162 | 0.84 | AKT1 (0.68) | PAK1ALDH1A1TSHRROCK2PRKACA | |
| SCHEMBL4017646 | 0.84 | GRM5 (0.53) | PAK1ALDH1A1TSHR | |
| SCHEMBL9966963 | 0.83 | JAK3 (0.56) | PAK1JAK3JAK1JAK2KIT | |
| SCHEMBL9967260 | 0.82 | JAK3 (0.56) | PAK1JAK3JAK1JAK2KIT | |
| SCHEMBL9966969 | 0.82 | JAK3 (0.57) | PAK1JAK3JAK1JAK2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| WO-2012080735-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | PAK1 43/4885JAK3 713/4885JAK1 107/4885 |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | PAK1 43/4885JAK3 713/4885JAK1 107/4885 |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | PAK1 43/4885JAK3 713/4885JAK1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.